The stock of Kazia Therapeutics Limited ADR (KZIA) has gone down by -27.20% for the week, with a 96.23% rise in the past month and a 38.74% rise in the past quarter. The volatility ratio for the week is 15.65%, and the volatility levels for the past 30 days are 16.49% for KZIA. The simple moving average for the last 20 days is 7.65% for KZIA stock, with a simple moving average of -44.30% for the last 200 days.
Is It Worth Investing in Kazia Therapeutics Limited ADR (NASDAQ: KZIA) Right Now?
Company’s 36-month beta value is 2.45.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The average trading volume of KZIA on June 24, 2025 was 846.81K shares.
KZIA) stock’s latest price update
Kazia Therapeutics Limited ADR (NASDAQ: KZIA)’s stock price has plunge by 250367relation to previous closing price of 9.15. Nevertheless, the company has seen a -27.20% plunge in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-11 that SYDNEY, June 11, 2025 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company pioneering next-generation oncology therapeutics, today announced the publication of transformative preclinical research in the journal Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research that underscores the powerful potential of its lead asset, paxalisib, in reshaping the treatment landscape for triple-negative breast cancer (TNBC), one of the most aggressive and treatment-resistant cancer subtypes. The preclinical program was conducted by Professor Sudha Rao at the renowned QIMR Berghofer Medical Research Institute, revealing how paxalisib can reprogram the tumor microenvironment and enhance immune response, showing substantial synergy with immune checkpoint inhibitors.
Analysts’ Opinion of KZIA
Many brokerage firms have already submitted their reports for KZIA stocks, with Maxim Group repeating the rating for KZIA by listing it as a “Buy.” The predicted price for KZIA in the upcoming period, according to Maxim Group is $3 based on the research report published on February 06, 2025 of the current year 2025.
Maxim Group, on the other hand, stated in their research note that they expect to see KZIA reach a price target of $18. The rating they have provided for KZIA stocks is “Buy” according to the report published on October 14th, 2021.
H.C. Wainwright gave a rating of “Buy” to KZIA, setting the target price at $17 in the report published on January 05th of the previous year.
KZIA Trading at 46.11% from the 50-Day Moving Average
After a stumble in the market that brought KZIA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.43% of loss for the given period.
Stock Fundamentals for KZIA
Current profitability levels for the company are sitting at:
- -11.47 for the present operating margin
- 1.0 for the gross margin
The net margin for Kazia Therapeutics Limited ADR stands at -10.79. The total capital return value is set at 6.76. Equity return is now at value -3028.18, with -135.08 for asset returns.
Based on Kazia Therapeutics Limited ADR (KZIA), the company’s capital structure generated -0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -15.11.
Currently, EBITDA for the company is -26.77 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 3.65. The receivables turnover for the company is 18.65for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.21.
Conclusion
In a nutshell, Kazia Therapeutics Limited ADR (KZIA) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
